Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 2, 2007 - Issue 2
Submit an article Journal homepage
37
Views
2
CrossRef citations to date
0
Altmetric
Review

Y2, Y4 receptors and obesity

En-Ju D Lin Research Officer, The Garvan Institute of Medical Research, Neuroscience Research Program, 384 Victoria Street, Darlinghurst NSW 2010, Sydney, Australia. [email protected]
,
Lei Zhang Research Officer, The Garvan Institute of Medical Research, Neuroscience Research Program, 384 Victoria Street, Darlinghurst NSW 2010, Sydney, Australia. [email protected]
,
Amanda Sainsbury Research Fellow, The Garvan Institute of Medical Research, Neuroscience Research Program, 384 Victoria Street, Darlinghurst NSW 2010, Sydney, Australia. [email protected]
&
Herbert Herzog Director of Neuroscience Research Program, The Garvan Institute of Medical Research, Neuroscience Research Program, 384 Victoria Street, Darlinghurst NSW 2010, Sydney, Australia. [email protected]
Pages 163-173 | Published online: 10 Jan 2014

References

  • Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat. Med.12, 62–66 (2006).
  • Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes. Rev.5(Suppl. 1), 4–104 (2004).
  • Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann. Intern. Med.138, 24–32 (2003).
  • Yanovski SZ, Yanovski JA. Obesity. N. Engl. J. Med.346, 591–602 (2002).
  • Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs65, 1391–1418 (2005).
  • Chaput JP, Berube-Parent S, Tremblay A. Obesity and cardiovascular physiology: impact of some pharmacological agents. Curr. Vasc. Pharmacol.3, 185–193 (2005).
  • Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology120, 669–681 (2001).
  • Korner J, Bessler M, Cirilo LJ et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J. Clin. Endocrinol. Metab.90, 359–365 (2005).
  • le Roux CW, Aylwin SJ, Batterham RL et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg.243, 108–114 (2006).
  • Batterham RL, Heffron H, Kapoor S et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab.4, 223–233 (2006).
  • Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev.20, 68–100 (1999).
  • Sainsbury A, Rohner-Jeanrenaud F, Cusin I et al. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia40, 1269–1277 (1997).
  • Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology115, 427–429 (1984).
  • Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology133, 1753–1758 (1993).
  • Bai FL, Yamano M, Shiotani Y et al. An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. Brain Res.331, 172–175 (1985).
  • Bagnasco M, Tulipano G, Melis MR, Argiolas A, Cocchi D, Muller EE. Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. Regul. Pept.111, 161–167 (2003).
  • Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc. Natl Acad. Sci. USA88, 10931–10935 (1991).
  • Sahu A, Kalra PS, Kalra SP. Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides9, 83–86 (1988).
  • Malabu UH, Kilpatrick A, Ware M, Vernon RG, Williams G. Increased neuropeptide Y concentrations in specific hypothalamic regions of lactating rats: possible relationship to hyperphagia and adaptive changes in energy balance. Peptides15, 83–87 (1994).
  • Abe M, Saito M, Ikeda H, Shimazu T. Increased neuropeptide Y content in the arcuato-paraventricular hypothalamic neuronal system in both insulin-dependent and non-insulin-dependent diabetic rats. Brain Res.539, 223–227 (1991).
  • Raposinho PD, Pedrazzini T, White RB, Palmiter RD, Aubert ML. Chronic neuropeptide Y infusion into the lateral ventricle induces sustained feeding and obesity in mice lacking either Npy1r or Npy5r expression. Endocrinology145, 304–310 (2004).
  • Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology137, 3–12 (1996).
  • Lin EJ, Sainsbury A, Lee NJ et al. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology147, 5094–5101 (2006).
  • McKibbin PE, Cotton SJ, McMillan S et al. Altered neuropeptide Y concentrations in specific hypothalamic regions of obese (fa/fa) Zucker rats. Possible relationship to obesity and neuroendocrine disturbances. Diabetes40, 1423–1429 (1991).
  • Williams G, Shellard L, Lewis DE et al. Hypothalamic neuropeptide Y disturbances in the obese (cp/cp) JCR:LA corpulent rat. Peptides13, 537–540 (1992).
  • Wilding JP, Gilbey SG, Bailey CJ et al. Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology132, 1939–1944 (1993).
  • Baranowska B, Wolinska-Witort E, Wasilewska-Dziubinska E, Roguski K, Martynska L, Chmielowska M. The role of neuropeptides in the disturbed control of appetite and hormone secretion in eating disorders. Neuro. Endocrinol. Lett.24, 431–434 (2003).
  • Bray MS, Boerwinkle E, Hanis CL. Linkage analysis of candidate obesity genes among the Mexican-American population of Starr County, Texas. Genet. Epidemiol.16, 397–411 (1999).
  • Ding B, Kull B, Liu Z et al. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul. Pept.127, 45–53 (2005).
  • Lin S, Boey D, Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides38, 189–200 (2004).
  • Iyengar S, Li DL, Simmons RM. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding? J. Pharmacol. Exp. Ther.289, 1031–1040 (1999).
  • Henry M, Ghibaudi L, Gao J, Hwa JJ. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes. Res.13, 36–47 (2005).
  • Erondu N, Gantz I, Musser B et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab.4, 275–282 (2006).
  • Duhault J, Boulanger M, Chamorro S et al. Food intake regulation in rodents: Y5 or Y1 NPY receptors or both? Can. J. Physiol. Pharmacol.78, 173–185 (2000).
  • Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature418, 650–654 (2002).
  • Asakawa A, Inui A, Yuzuriha H et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology124, 1325–1336 (2003).
  • Michel MC, Beck-Sickinger A, Cox H et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev.50, 143–150 (1998).
  • Upchurch BH, Fung BP, Rindi G, Ronco A, Leiter AB. Peptide YY expression is an early event in colonic endocrine cell differentiation: evidence from normal and transgenic mice. Development122, 1157–1163 (1996).
  • Renshaw D, Batterham RL. Peptide YY: a potential therapy for obesity. Curr. Drug Targets6, 171–179 (2005).
  • Blomqvist AG, Herzog H. Y-receptor subtypes – how many more? Trends Neurosci.20, 294–298 (1997).
  • Grandt D, Schimiczek M, Beglinger C et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36. Regul. Pept.51, 151–159 (1994).
  • Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3–36. N. Engl. J. Med.349, 941–948 (2003).
  • Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology89, 1070–1077 (1985).
  • Onaga T, Zabielski R, Kato S. Multiple regulation of peptide YY secretion in the digestive tract. Peptides23, 279–290 (2002).
  • Chelikani PK, Haver AC, Reidelberger RD. Comparison of the inhibitory effects of PYY(3–36) and PYY(1–36) on gastric emptying in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol.287, R1064–R1070 (2004).
  • Scott V, Kimura N, Stark JA, Luckman SM. Intravenous peptide YY3–36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J. Neuroendocrinol17, 452–457 (2005).
  • Tschop M, Castaneda TR, Joost HG et al. Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature430(6996), 1 p following 165; discussion 2 p following 165 (2004).
  • Boggiano MM, Chandler PC, Oswald KD et al. PYY3–36 as an anti-obesity drug target. Obes. Rev.6, 307–322 (2005).
  • Pfluger PT, Kampe J, Castaneda TR et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3–36. J. Clin. Endocrinol. Metab.92(2), 583–588 (2006).
  • Feletou M, Levens NR. Neuropeptide Y2 receptors as drug targets for the central regulation of body weight. Curr. Opin. Investig. Drugs6, 1002–1011 (2005).
  • Challis BG, Coll AP, Yeo GS et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3–36). Proc. Natl Acad. Sci. USA101, 4695–4700 (2004).
  • Pittner RA, Moore CX, Bhavsar SP et al. Effects of PYY[3–36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord.28, 963–971 (2004).
  • Martin NM, Small CJ, Sajedi A, Patterson M, Ghatei MA, Bloom SR. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3–36) but resistant to ghrelin. Int. J. Obes. Relat. Metab. Disord.28, 886–893 (2004).
  • Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR Jr. Effects of peptide YY[3–36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology145, 4967–4975 (2004).
  • Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O’Rahilly S. Acute effects of PYY3–36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys. Res. Commun.311, 915–919 (2003).
  • Ghamari-Langroudi M, Colmers WF, Cone RD. PYY3–36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors. Cell Metab.2, 191–199 (2005).
  • Halatchev IG, Cone RD. Peripheral administration of PYY(3–36) produces conditioned taste aversion in mice. Cell Metab.1, 159–168 (2005).
  • Naveilhan P, Hassani H, Canals JM et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat. Med.5, 1188–1193 (1999).
  • Sainsbury A, Schwarzer C, Couzens M et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl Acad. Sci. USA99, 8938–8943 (2002).
  • Abbott CR, Small CJ, Sajedi A et al. The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat. Int. J. Obes. (Lond.)30, 288–292 (2006).
  • Lin S, Lin EJ, Boey D et al. Fasting inhibits the growth and reproductive axes via distinct Y2 and Y4 receptor mediated pathways. Endocrinology (2007) (Epub ahead of print).
  • Sainsbury A, Baldock PA, Schwarzer C et al. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol. Cell Biol.23, 5225–5233 (2003).
  • Sainsbury A, Bergen HT, Boey D et al. Y2Y4 receptor double knockout protects against obesity due to a high-fat diet or Y1 receptor deficiency in mice. Diabetes55, 19–26 (2006).
  • Sainsbury A, Schwarzer C, Couzens M, Herzog H. Y2 receptor deletion attenuates the Type 2 diabetic syndrome of ob/ob mice. Diabetes51, 3420–3427 (2002).
  • Naveilhan P, Svensson L, Nystrom S, Ekstrand AJ, Ernfors P. Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation. Peptides23, 1087–1091 (2002).
  • Allison SJ, Baldock P, Sainsbury A et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J. Biol. Chem.281, 23436–23444 (2006).
  • Baldock PA, Sainsbury A, Couzens M et al. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest.109, 915–921 (2002).
  • Schonhoff S, Baggio L, Ratineau C et al. Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol. Cell Biol.25, 4189–4199 (2005).
  • Ludwig DS, Tritos NA, Mastaitis JW et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest.107, 379–386 (2001).
  • Chen N, Liu L, Zhang Y, Ginsberg HN, Yu YH. Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue. Diabetes54, 3379–3386 (2005).
  • Boey D, Heilbronn L, Sainsbury A et al. Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with Type 2 diabetes. Neuropeptides40, 317–324 (2006).
  • Oliveira KJ, Paula GS, Costa ESRH et al. Peptide YY (PYY)3–36 modulates thyrotropin secretion in rats. J. Endocrinol.191, 459–463 (2006).
  • Takeda S, Elefteriou F, Levasseur R et al. Leptin regulates bone formation via the sympathetic nervous system. Cell111, 305–317 (2002).
  • Potter EK, Tripovic D. Modulation of sympathetic neurotransmission by neuropeptide Y Y2 receptors in rats and guinea pigs. Exp. Brain Res.173, 346–352 (2006).
  • Malmstrom RE, Lundberg JN, Weitzberg E. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo. Naunyn Schmiedebergs Arch. Pharmacol.365, 106–111 (2002).
  • Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley MA, Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J. Clin. Endocrinol. Metab.90, 6386–6391 (2005).
  • Stock S, Leichner P, Wong AC et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J. Clin. Endocrinol. Metab.90, 2161–2168 (2005).
  • le Roux CW, Batterham RL, Aylwin SJ et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology147, 3–8 (2006).
  • Ma L, Tataranni PA, Hanson RL et al. Variations in peptide YY and Y2 receptor genes are associated with severe obesity in Pima Indian men. Diabetes54, 1598–1602 (2005).
  • Torekov SS, Larsen LH, Andersen G et al. Variants in the 5´ region of the neuropeptide Y receptor Y2 gene (NPY2R) are associated with obesity in 5,971 white subjects. Diabetologia49, 2653–2658 (2006).
  • Lavebratt C, Alpman A, Persson B, Arner P, Hoffstedt J. Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Int. J. Obes. (Lond.)30, 453–459 (2006).
  • Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ. Distribution and release of human pancreatic polypeptide. Gut17, 940–944 (1976).
  • Schwartz TW. Pancreatic polypeptide: a unique model for vagal control of endocrine systems. J. Auton. Nerv. Syst.9, 99–111 (1983).
  • Havel PJ, Akpan JO, Curry DL, Stern JS, Gingerich RL, Ahren B. Autonomic control of pancreatic polypeptide and glucagon secretion during neuroglucopenia and hypoglycemia in mice. Am. J. Physiol.265, R246–254 (1993).
  • Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc. Soc. Exp. Biol. Med.202, 44–63 (1993).
  • McTigue DM, Rogers RC. Pancreatic polypeptide stimulates gastric motility through a vagal-dependent mechanism in rats. Neurosci. Lett.188, 93–96 (1995).
  • Adrian TE, Greenberg GR, Besterman HS, Bloom SR. Pharmacokinetics of pancreatic polypeptide in man. Gut19, 907–909 (1978).
  • Balasubramaniam A, Mullins DE, Lin S et al. Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32–36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. J. Med. Chem.49, 2661–2665 (2006).
  • Sainsbury A, Schwarzer C, Couzens M et al. Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev.16, 1077–1088 (2002).
  • Ueno N, Inui A, Iwamoto M et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology117, 1427–1432 (1999).
  • Smith-White MA, Herzog H, Potter EK. Cardiac function in neuropeptide Y Y4 receptor-knockout mice. Regul. Pept.110, 47–54 (2002).
  • Tomita T, Greeley G Jr, Watt L, Doull V, Chance R. Protein meal-stimulated pancreatic polypeptide secretion in Prader–Willi syndrome of adults. Pancreas4, 395–400 (1989).
  • Lassmann V, Vague P, Vialettes B, Simon MC. Low plasma levels of pancreatic polypeptide in obesity. Diabetes29, 428–430 (1980).
  • Marco J, Zulueta MA, Correas I, Villanueva ML. Reduced pancreatic polypeptide secretion in obese subjects. J. Clin. Endocrinol. Metab.50, 744–747 (1980).
  • Pieramico O, Malfertheiner P, Nelson DK, Glasbrenner B, Ditschuneit H. Interdigestive cycling and post-prandial release of pancreatic polypeptide in severe obesity. Int. J. Obes.14, 1005–1011 (1990).
  • Wisen O, Bjorvell H, Cantor P, Johansson C, Theodorsson E. Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul. Pept.39, 43–54 (1992).
  • Hjalmarsen A, Bremnes RM, Aasebo U, Jorde R. Pancreatic polypeptide is increased in patients with advanced malignant disease. Anticancer Res.24, 2515–2517 (2004).
  • Uhe AM, Szmukler GI, Collier GR, Hansky J, O’Dea K, Young GP. Potential regulators of feeding behavior in anorexia nervosa. Am. J. Clin. Nutr.55, 28–32 (1992).
  • Fujimoto S, Inui A, Kiyota N et al. Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Biol. Psychiatry41, 1068–1070 (1997).
  • Lieverse RJ, Masclee AA, Jansen JB, Lamers CB. Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion and modified sham feeding in lean and obese persons. Int. J. Obes. Relat. Metab. Disord.18, 123–127 (1994).
  • Koska J, DelParigi A, de Courten B, Weyer C, Tataranni PA. Pancreatic polypeptide is involved in the regulation of body weight in pima Indian male subjects. Diabetes53, 3091–3096 (2004).
  • Batterham RL, Le Roux CW, Cohen MA et al. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab.88, 3989–3992 (2003).
  • Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr. Rev.27(7), 719–727 (2006).
  • Schmidt PT, Naslund E, Gryback P et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J. Clin. Endocrinol. Metab.90, 5241–5246 (2005).
  • Berntson GG, Zipf WB, O’Dorisio TM, Hoffman JA, Chance RE. Pancreatic polypeptide infusions reduce food intake in Prader–Willi syndrome. Peptides14, 497–503 (1993).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.